24
views
0
recommends
+1 Recommend
1 collections
    0
    shares

      Call for Papers: Novel Methods in Vascular and Lymphatic Physiology

      Submit here by June 30, 2025

      About Journal of Vascular Research: 1.8 Impact Factor I 3.4 CiteScore I 0.486 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found

      Selective Afterload Reduction in the Treatment of Septal Rupture Complicating Myocardial Infarction

      case-report
      ,
      Cardiology
      S. Karger AG
      Hydralazine, Ventricular septal defect, Afterload reduction, Myocardial infarction

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Interventricular septal rupture complicating acute myocardial infarction is usually fatal unless corrective surgery can be delayed until adequate healing of the septum has occurred. A case is reported in which the degree of shunting through the ventricular septal defect was reduced by the use of hydralazine, a drug which selectively reduces peripheral vascular resistance. In spite of the fact that this patient eventually died before surgical repair could be carried out, the hydralazine did bring about a significant improvement in the left-to-right shunt ratio.

          Related collections

          Author and article information

          Journal
          CRD
          Cardiology
          10.1159/issn.0008-6312
          Cardiology
          S. Karger AG
          0008-6312
          1421-9751
          1980
          1980
          31 October 2008
          : 65
          : 1
          : 59-64
          Affiliations
          Cardiac Care Unit, Division of Cardiology, Medical Service, St. Luke’s Hospital Center, New York, N.Y
          Article
          170795 Cardiology 1980;65:59–64
          10.1159/000170795
          7363281
          53307a2b-d14e-4a8d-a583-90a27c2bd96c
          © 1980 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          Page count
          Pages: 6
          Categories
          Original Paper

          General medicine,Neurology,Cardiovascular Medicine,Internal medicine,Nephrology
          Hydralazine,Ventricular septal defect,Myocardial infarction,Afterload reduction

          Comments

          Comment on this article

          Related Documents Log